Влияние гуморальных факторов гомеостатической пролиферации на T-регуляторные клетки in vitro

Цель – изучение влияния гуморальных факторов гомеостатической пролиферации интерлейкина (IL) 7 и IL-15 на фенотипические и функциональные характеристики T-регуляторных клеток у здоровых доноров in vitro.

Материалы и методы. В исследование были включены 15 условно здоровых доноров. Методом проточной цитометрии проводились фенотипирование, оценка экспрессии FoxP3 и основных функциональных молекул T-регуляторных клеток (CTLA-4, PD-L1, HLA-D) до и после культивирования с IL-7 и IL-15, а также с анти-CD3-антителами в комбинации с IL-2. Оценивался пролиферативный ответ T-регуляторных клеток на стимуляцию указанными факторами.

Результаты. Обнаружено, что факторы гомеостатической пролиферации способствуют сохранению фенотипа CD4+CD25+FoxP3+ и численному поддержанию T-регуляторных лимфоцитов в культуре, а также могут положительно влиять на экспрессию таких функциональных молекул, как PD-L1 и HLA-DR. Кроме того показано, что указанные факторы способны вызывать пролиферацию T-регуляторных клеток в существенно более низкой степени, чем CD4+-лимфоцитов.

Заключение. Выявлена способность гомеостатических факторов IL-7 и IL-15 поддерживать фенотип T-регуляторных клеток и экспрессию функциональных маркеров. По-видимому, это играет важную роль в условиях лимфопении при снижении числа эффекторных лимфоцитов – основных продуцентов IL-2, которому отводится первостепенная роль в гомеостазе T-регуляторных клеток в норме.

1. Moxham V.F., Karegli J., Phillips R.E., Brown K.L., Tapmeier T.T., Hangartner R., Sacks S.H., Wong W. Homeostatic proliferation of lymphocytes results in augmented memory-like function and accelerated allograft rejection. J. Immunol. 2008; Mar. 15; 180 (6): 3910–3918. DOI: 10.4049/jimmunol.180.6.3910.

2. Bolton H.A., Zhu E., Terry A.M., Guy T.V., Koh W.P., Tan S.Y., Power C.A., Bertolino P., Lahl K., Sparwasser T., Shklovskaya E., Fazekas de St Groth B. Selective Treg reconstitution during lymphopenia normalizes DC costimulation and prevents graft-versus-host disease. J. Clin. Invest. 2015; 125 (9): 3627–3641. DOI: 10.1172/JCI76031.

3. Miller C.N., Hartigan-O’Connor D.J., Lee M.S., Laidlaw G., Cornelissen I. P., Matloubian M., Coughlin S.R., McDonald D.M., McCune J.M. IL-7 production in murine lymphatic endothelial cells and induction in the setting of peripheral lymphopenia. Int. Imm. 2013; 25 (8): 471–483. DOI: 10.1093/intimm/dxt012.

4. Schluns K.S., Rivas S., Stonier S.W, Colpitts S.L., Anthony S.M. Expression of IL-15 is differentially regulated during lymphopenia depending on the method of induction. The Journal of Immunology. 2016; May 1, 196 (1 Supplement): 196.15.

5. Theofilopoulos A.N., Dummer W., Kono D.H. T cell homeostasis and systemic autoimmunity. The Journal of Сlinical Investigation. 2001; 108 (3): 335–340. DOI: 10.1172/JCI12173.

6. Ge Q., Rao V.P., Cho B.K., Eisen H.N., Chen J. Dependence of lymphopenia-induced T cell proliferation on the abundance of peptide/MHC epitopes and strength of their interaction with T cell receptors. Proc. Natl. Acad. Sci. USA. 2001; 98 (4): 1728–1733. DOI: 10.1073/pnas.98.4.1728.

7. Kieper W.C., Burghardt J.T., Surh C.D. A role for TCR affinity in regulating naive T cell homeostasis. J. Immunol. 2004; 172 (1): 40–44. DOI: 10.4049/jimmunol.172.1.40.

8. Jones J.L., Thompson S.A.J., Loh P., Davies J.L., Tuohy O.C., Curry A.J., Azzopardi L., Hill-Cawthorne G., Fahey M.T., Compston A., Coles A.J. Human autoimmunity after lymphocyte depletion is caused by homeostatic T-cell proliferation. PNAS. 2013, 110 (50): 20200-02025. DOI: 10.1073/pnas.1313654110.

9. Komatsu N., Okamoto K., Sawa S., Nakashima T.,Oh-hora M., Kodama T., Tanaka S., Bluestone J.A., Takayanagi H. Pathogenic conversion of Foxp3+ T-cells into TH17 cells in autoimmune arthritis. Nat. Med. 2014; 20 (1): 62–70. DOI: 10.1038/nm.3432.

10. Duarte J.H., Zelenay S., Bergman M.L., Martins A.C., Demengeot J. Natural Treg cells spontaneously differentiate into pathogenic helper cells in lymphopenic conditions. Eur. J. Immunol. 2009; 39: 948–955. DOI: 10.1002/eji.200839196.

11. Chevalier N., Thorburn A.N., Macia L., Tan J., Juglair L., Yagita H., Yu D., Hansbro P.M., Mackay C.R. Inflammation and lymphopenia trigger autoimmunity by suppression of IL-2-controlled regulatory T cell and increase of IL-21-mediated effector T cell expansion. J. Immunol. 2014; 193 (10): 4845–4858. DOI: 10.4049/jimmunol.1302966.

12. Bayer A.L., Lee J.Y., de la Barrera A., Surh C.D., Malek T.R. A function for IL-7R for CD4+CD25+Foxp3+ T regulatory cells. J. Immunol. 2008; 181 (1): 225–234.

13. Simonetta F., Gestermann N., Martinet K.Z., Boniotto M., Tissiиres P., Seddon B., Bourgeois C. Interleukin-7 influences FOXP3+CD4+ regulatory T cells peripheral homeostasis. PLoS One. 2012; 7 (5): e36596. DOI: 10.1371/journal.pone.0036596.

14. Younas M., Hue S., Lacabaratz C., Guguin A., Wiedemann A., Surenaud M., Beq S., Croughs T., Leliиvre J.D., Lévy Y. IL-7 modulates in vitro and in vivo human memory T regulatory cell functions through the CD39/ ATP axis. J. Immunol. 2013; Sep. 15; 191 (6): 3161–3168. DOI: 10.4049/jimmunol.1203547.

15. Xia J., Liu W., Hu B., Tian Z., Yang Y. IL-15 promotes regulatory T cell function and protects against diabetes development in NK-depleted NOD mice. Clin. Immunol. 2010; 134 (2): 130–139. DOI: 10.1016/j.clim.2009.09.011.

16. Ben A.M., Belhadj H.N., Moes N., Buyse S., Abdeladhim M., Louzir H., Cerf-Bensussan N. IL-15 renders conventional lymphocytes resistant to suppressive functions of regulatory T cells through activation of the phosphatidylinositol 3-kinase pathway. J. Immunol. 2009, 182 (11): 6763–6770. DOI: 10.4049/jimmunol.0801792.

17. Suzuki H., Kündig T.M., Furlonger C., Wakeham A., Timms E., Matsuyama T., Schmits R., Simard J.J., Ohashi P.S., Griesser H. Deregulated T cell activation and autoimmunity in mice lacking interleukin-2 receptor beta. Science. 1995, 268 (5216): 1472–1476.

18. Malek T.R., Castro I. Interleukin-2 receptor signaling: at the interface between tolerance and immunity. Immunity. 2010. 33 (2): 153–165. DOI: 10.1016/j.immuni.2010.08.004.

19. Chinen T., Kannan A.K., Levine A.G., Fan X., Klein U., Zheng Y., Gasteiger G., Feng Y., Fontenot J.D., Rudensky A.Y. An essential role for the IL-2 receptor in Treg cell function. Nat. Immunol. 2016; Nov. 17 (11): 1322– 1333. DOI: 10.1038/ni.3540.

20. Sharfe N., Dadi H.K., Shahar M., Roifman C.M. Human immune disorder arising from mutation of the alpha chain of the interleukin-2 receptor. Proc. Natl. Acad. Sci. USA. 1997; 94 (7): 3168–3171.

21. Goudy K., Aydin D., Barzaghi F., Gambineri E., Vignoli M., Ciullini M.S., Doglioni C., Ponzoni M., Cicalese M.P., Assanelli A., Tommasini A., Brigida I., Dellepiane R.M., Martino S., Olek S., Aiuti A., Ciceri F., Roncarolo M.G., Bacchetta R. Human IL2RA null mutation mediates immunodeficiency with lymphoproliferation and autoimmunity. Clin. Immunol. 2013; Mar. 146 (3): 248–261. DOI: 10.1016/j.clim.2013.01.004.

22. Jeon P.H., Oh K.I. IL2 is required for functional maturation of regulatory T cells. Animal Cells and Systems. 2017, 21 (1): 1–9. DOI: 10.1080/19768354.2016.1272489.

23. Owen D.L., Mahmud S.A., Vang K.B., Kelly R.M., Blazar B.R., Smith K.A., Farrar M.A. Identification of сellular sources of IL-2 needed for regulatory T сell development and homeostasis. J. Immunol. 2018; Jun. 15; 200 (12): 3926–3933. DOI: 10.4049/jimmunol.1800097.

24. Almeida A.R., Zaragoza B., Freitas A.A. Indexation as a novel mechanism of lymphocyte homeostasis: the number of CD4+CD25+ regulatory T cells is indexed to the number of IL-2-producing cells. J. Immunol. 2006; 177 (1): 192–200.

25. Vang K.B., Yang J., Mahmud S.A., Burchill M.A.,Vegoe A.L., Farrar M.A. Interleukin-2, -7 and -15, but not TSLP, redundantly govern CD4+Foxp3+ regulatory T сell development. J. Immunol. 2008; Sep. 1, 181 (5): 3285–3290

26. Jain N., Nguyen H., Chambers C., Kang J. Dual function of CTLA-4 in regulatory T cells and conventional T cells to prevent multiorgan autoimmunity. Proc. Nat. Acad. Sci. USA. 2010; Jan. 26; 107 (4): 1524–1528. DOI: 10.1073/pnas.0910341107.

27. Dai S., Jia R., Zhang X., Fang Q., Huang L. The PD-1/ PD-Ls pathway and autoimmune diseases. Cell Immunol. 2014; Jul. 290 (1): 72–79. DOI: 10.1016/j.cellimm.2014.05.006.

28. Francisco L.M., Salinas V.H., Brown K.E., Vanguri V.K., Freeman G.J., Kuchroo V.K., Sharpe A.H. PD-L1 regulates the development, maintenance, and function of induced regulatory T cells. J. Exp. Med. 2009; Dec. 2; 206. (13): 3015–3029. DOI: 10.1084/jem.20090847.

29. Kinter A.L., Godbout E.J., McNally J.P., Sereti I., Roby G.A., O’Shea M.A., Fauci A.S. The common gamma-chain cytokines IL-2, IL-7, IL-15, and IL-21 induce the expression of programmed death-1 and its ligands. J. Immunol. 2008; Nov. 15, 181 (10): 6738–6746.

30. Baecher-Allan C., Wolf E., Hafler D.A. MHC class II expression identifies functionally distinct human regulatory T cells. J. Immunol. 2006; Apr. 15; 176 (8): 4622–4631.

31. Zou T., Caton A.J. Dendritic сells induce regulatory T cell proliferation through antigen-dependent and independent interactions. The Journal of Immunology. 2010; 185 (5): 2790–2799. DOI: 10.4049/jimmunol.0903740.

32. Zou T., Satake A., Corbo E., Schmidt A.M., Farrar M.A., Maltzman J.S., Kambayashi T. Cutting edge: IL-2 signals determine the degree of TCR signaling necessary to support regulatory T cell proliferation in vivo. J. Immunol. 2012; 189 (1): 28–32. DOI: 10.4049/jimmunol.1200507.

33. Nishio J., Feuerer M., Wong J., Mathis D., Benoist C. Anti-CD3 therapy permits regulatory T cells to surmount T cell receptor-specified peripheral niche constraints. J. Exp. Med. 2010; 207 (9):1879–1889. DOI: 10.1084/jem.20100205.

34. Walker L.S., Chodos A., Eggena M., Dooms H., Abbas A.K. Antigen-dependent proliferation of CD4+ CD25+ regulatory T cells in vivo. J. Exp. Med. 2003; Jul. 21;198 (2): 249–258.